Chordate Medical CEO presents the company and Ozilia at Aktieportföljen Live

On Tuesday, October 15th, at 11:15, Chordate's CEO Anders Weilandt will participate at the investor event Aktieportföljen. He will present the latest developments in the company, such as the first migraine order from Saudi Arabia, the breakthrough in Switzerland and the progress on the other focus markets, the new patent in the US, as well as the next step of the exit-strategy.

"It is important for us to get out and meet both existing and potential new shareholders. We want to seize every opportunity to inform the market, and Aktieportföljen gathers a large investor community," says Anders Weilandt, Chordate CEO.

Aktieportföljen runs an investor network on Facebook in Sweden and Denmark with a total of 150,000 members.

Aktieportföljen Live can be streamed on Direkt Studios Youtube channel, and viewed on-demand in the Aktieportföljen Facebook group.

More press releases

We are a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.

We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

IR contact